We continue to look for greater confidence that there can be meaningful upside to estimates in 2026. Certainly, this update is a good first step in that direction. And with the company having several irons in the fire that could make the intermediate-term growth higher than anticipated— including in MRD, Ambry, additional data and services contracts, and pricing tailwinds for xF and xR post FDA approval—the company should have the ammo to deliver it. Timing of when these begin to manifest themselves, however, is a key consideration of an upgrade thesis and as a result, we reiterate our Market Perform.